Actively Recruiting

Phase Not Applicable
Age: 40Years - 85Years
All Genders
NCT06201455

Evaluation of Phacogoniotomy in Medically-controlled POAG

Led by Sun Yat-sen University · Updated on 2024-12-11

100

Participants Needed

1

Research Sites

326 weeks

Total Duration

On this page

Sponsors

S

Sun Yat-sen University

Lead Sponsor

W

West China Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are: * Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG. * Whether the PEI+GT has value of health economics. Participants will be randomized to receive either PEI+GT or PEI+MED, and followed up with a 1-year period as a primary outcome.

CONDITIONS

Official Title

Evaluation of Phacogoniotomy in Medically-controlled POAG

Who Can Participate

Age: 40Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 40 and 85 years, any gender
  • Diagnosed with primary open-angle glaucoma (POAG)
  • Intraocular pressure controlled under 1 to 4 topical hypotensive medications, IOP c= 24 mmHg
  • Mean deviation for visual field test e= -16 dB
  • Presence of clinically significant cataract and best-corrected visual acuity c= 0.63 on ETDRS chart
  • Voluntary participation with informed consent and agreement to follow-up visits according to protocol
Not Eligible

You will not qualify if you...

  • Any history of intraocular surgery or eye trauma
  • Other types of glaucoma such as primary angle-closure glaucoma or secondary glaucoma (including pigmentary, steroid-induced, angle-recession, neovascular, inflammatory, pseudoexfoliation syndrome)
  • Severe eye diseases affecting eye measurements or visual field testing
  • Axial eye length greater than 28 mm
  • Monophthalmia with best-corrected visual acuity of non-study eye less than 0.01
  • Severe systemic diseases affecting the whole body
  • Pregnant or breastfeeding women
  • If both eyes qualify, only the eye with worse vision is included

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, China, 510060

Actively Recruiting

Loading map...

Research Team

X

Xiulan Zhang, MD. PhD

CONTACT

Y

Yunhe Song, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here